

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL
for FY 2003

Effective 01/01/2003. Patent fees are subject to annual revision.

Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$ 180.00)

Complete if Known

Application Number	09/697,206
Filing Date	October 26, 2000
First Named Inventor	Daniel E. H. AFAR
Examiner Name	M. Davis
Art Unit	1642
Attorney Docket No.	511582002100

METHOD OF PAYMENT (check all that apply)

Check Credit Card Money Order Other None
 Deposit Account

Deposit Account Number 03-1952 referencing 511582002100

Deposit Account Name Morrison & Foerster LLP


The Director is hereby authorized to: (check all that apply)

Charge fee(s) indicated below Credit any overpayments
 Charge any additional fee(s) during the pendency of this application
 Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.


FEE CALCULATION (continued)**3. ADDITIONAL FEES**

Large Entity	Small Entity	Fee Description	Fee Paid
Fee Code (\$)	Fee Code (\$)	Fee Description	Fee Paid
1051 130	2051 65	Surcharge - late filing fee or oath	
1052 50	2052 25	Surcharge - late provisional filing fee or cover sheet	
1053 130	1053 130	Non-English specification	
1812 2,520	1812 2,520	For filing a request for ex parte reexamination	
1804 920*	1804 920*	Requesting publication of SIR prior to Examiner action	
1805 1,840*	1805 1,840*	Requesting publication of SIR after Examiner action	
1251 110	2251 55	Extension for reply within first month	
1252 410	2252 205	Extension for reply within second month	
1253 930	2253 465	Extension for reply within third month	
1254 1,450	2254 725	Extension for reply within fourth month	
1255 1,970	2255 985	Extension for reply within fifth month	
1401 320	2401 160	Notice of Appeal	
1402 320	2402 160	Filing a brief in support of an appeal	
1403 280	2403 140	Request for oral hearing	
1451 1,510	1451 1,510	Petition to institute a public use proceeding	
1452 110	2452 55	Petition to revive - unavoidable	
1453 1,300	2453 650	Petition to revive - unintentional	
1501 1,300	2501 650	Utility issue fee (or reissue)	
1502 470	2502 235	Design issue fee	
1503 630	2503 315	Plant issue fee	
1460 130	1460 130	Petitions to the Commissioner	
1807 50	1807 50	Processing fee under 37 CFR 1.17(q)	
1806 180	1806 180	Submission of Information Disclosure Stmt	180.00
8021 40	8021 40	Recording each patent assignment per property (times number of properties)	
1809 750	2809 375	Filing a submission after final rejection (37 CFR 1.129(a))	
1810 750	2810 375	For each additional invention to be examined (37 CFR 1.129(b))	
1801 750	2801 375	Request for Continued Examination (RCE)	
1802 900	1802 900	Request for expedited examination of a design application	
Other fee (specify)			
*Reduced by Basic Filing Fee Paid			
SUBTOTAL (3) (\$ 180.00)			

**or number previously paid, if greater; For Reissues, see above

SUBMITTED BY				Complete (if applicable)	
Name (Print/Type)	David L. Devernoe	Registration No. (Attorney/Agent)	50,128	Telephone	(858) 720-7943
Signature				Date	August 27, 2003

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 8/27/03 Signature:  (Judy Bridgwater)

BEST AVAILABLE COPY



16425

PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>		Application Number	09/697,206
		Filing Date	October 26, 2000
		First Named Inventor	Daniel E. H. AFAR
		Art Unit	1642
		Examiner Name	M. Davis
Total Number of Pages in This Submission	12	Attorney Docket Number	511582002100

ENCLOSURES (check all that apply)			
<input checked="" type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement - Supplemental <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 1) Form 1449 2) References: 143 3. Return Postcard	
Remarks Customer No. 25225			

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	MORRISON & FOERSTER LLP David L. Devernoe - 50,128
Signature	
Date	August 27, 2003

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 8/27/03 Signature: Judy Bridgwater (Judy Bridgwater)



PATENT
Docket No. 511582002100

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on August 27, 2003.

Judy Bridgwater
Judy Bridgwater

RECEIVED
SEP 09 2003
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Daniel E. H. AFAR et al.

Serial No.: 09/697,206

Filing Date: October 26, 2000

For: NOVEL GENE UPREGULATED IN
CANCERS OF THE PROSTATE

Examiner: M. Davis

Group Art Unit: 1642

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA, 22313

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents are also submitted herewith. The Examiner is requested to make these documents of record.

09/08/2003 JADDD1 00000052 031952 09697206

01 FC:1806 180.00 DA

sd-161894

This Information Disclosure Statement is submitted:

- With the application; accordingly, no fee or separate requirements are required.
- Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.
- After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - A fee is required. A check in the amount of * is enclosed.
 - A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly; no fee is believed to be due.
- After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the amount of * is enclosed.
 - A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to

charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 511582002100. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: August 27, 2003

Respectfully submitted,

By: 

David L. Devernoe
Registration No. 50,128

Morrison & Foerster LLP
3811 Valley Centre Drive
Suite 500
San Diego, California 92130-2332
Telephone: (858) 720-7943
Facsimile: (858) 720-5125

<p>Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)</p> <p>RECEIVED SEP 9 2003 TECH CENTER 1600/2800</p> 		Docket Number 511582002100		Application Number 09/697,206	
		Applicant		Daniel E.H. AFAR et al.	
		Filing Date October 26, 2000		Group Art Unit 1642	
		Mailing Date August 27, 2003			

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	12/1979	4,179,337	Davis et al.	435	181	
	2.	11/1981	4,301,144	Iwashita et al.	424	78	
	3.	01/1985	4,496,689	Mitra	525	54.1	
	4.	02/1987	4,640,835	Shimizu et al.	424	94	
	5.	06/1987	4,670,417	Iwasaki et al.	514	6	
	6.	04/1988	4,736,866	Leder et al.	800	1	
	7.	12/1988	4,791,192	Nakagawa et al.	530	399	
	8.	09/1989	4,870,009	Evans et al.	435	70	
	9.	01/1995	5,382,510	Levine et al.	435	6	
	10.	06/1995	5,428,130	Capon et al.	530	350	
	11.	03/1998	5,723,286	Dower et al.	435	5	
	12.	03/1998	5,733,731	Schatz et al.	435	6	
	13.	11/1998	5,837,501	Beumer et al.	435	91.2	
	14.	11/1998	5,840,501	Allard et al.	435	74	
	15.	12/1998	5,846,722	Kauvar et al.	435	6	
	16.	07/1999	5,919,652	Pang et al.	435	69.1	
	17.	07/1999	5,925,523	Dove et al.	435	6	
	18.	07/1999	5,928,868	Liu et al.	435	6	
	19.	08/1999	5,939,533	Lilja et al.	530	387.7	
	20.	09/1999	5,952,170	Stroun et al.	435	6	
	21.	09/1999	5,955,280	Vidal et al.	435	6	
	22.	12/1999	6,004,746	Brent et al.	435	6	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
-------------------	----------	------	--------------	---------	-------	----------	--------------------

EXAMINER: _____ DATE CONSIDERED: _____

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SEP 05 2003

PATENT & TRADEMARK OFFICE

U.S. DEPARTMENT OF COMMERCE

Form PTO-1449

INFORMATION DISCLOSURE STATEMENT
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 511582002100

Application Number 09/697,206

Applicant

Daniel E.H. AFAR et al.

Filing Date October 26, 2000

Group Art Unit 1600

Mailing Date August 27, 2003

	23.	04/1998	WO 98/16628	WIPO				
	24.	06/1998	WO 98/24893	WIPO				

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	25. /	Alanen et al., Pathol. Res. Pract. (1996) 192(3):233-237
	26. /	Alers et al., Lab. Invest. (1997) 77(5):437-438
	27. /	Altschul et al., Methods in Enzymology (1996) 266:460-480
	28.	Arlen et al., Crit. Rev. Immunol. (1998) 18:133-138
	29.	Arthur et al., Cancer Gene Ther. (1997) 4:17-25
	30.	Ashley et al., J. Exp. Med. (1997) 186:1177-1182
	31.	Baisden et al., Am. J. Surg. Pathol. (1999) 23(8):918-924
	32.	Beerli et al., J. Biol. Chem. (1994) 269:23931-23936
	33.	Bocking et al., Anal. Quant. Cytol. (1984) 6(2):74-88
	34.	Brooks et al., Cancer Epidemiol. Biomarkers Prev. (1998) 7:531-536
	35.	Bzdega et al., J. Neurochem. (1997) 69:2270
	36.	Caetano-Anolles, Biotechniques (1998) 25(3):472-476, 478-480
	37.	Carter et al., Nucl. Acids Res. (1986) 13:4331
	38.	Carter et al., Proc. Natl. Acad. Sci. USA (1993) 89:4285
	39.	Carter et al., Proc. Natl. Acad. Sci. USA (1996) 93:749
	40.	Chen et al., Lab. Invest. (1998) 78(2):165-174
	41.	Chothia, J. Mol. Biol. (1976) 150:1
	42.	Cohen, Oligodeoxynucleotides, Antisense Inhibitors of Gene Expression, CRC Press; and Synthesis (1988) 1:1-5
	43.	Couture and Stinchcomb, Trends Genet. (1996) 12:510-515
	44.	Cupp and Osterling, Mayo Clinic Proc. (1993) 68:297-306
	45.	De Marzo et al., Am. J. Pathol. (1999) 155(6):1985-1992
	46.	Dennis et al., Biochim. Biophys. Acta (1999) 1473(1):21-34
	47.	Deshane et al., Gene Ther. (1994) 1:332-337
	48.	Donnelly et al., Ann. Rev. Immunol. (1997) 15:617-648

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

O I P E
SEP 05 2003
JC22

PATENT & TRADEMARK OFFICE

Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 511582002100

Application Number 09/697,206

Applicant

Daniel E.H. AFAR et al.

Filing Date October 26, 2000

Group Art Unit 1642

Mailing Date August 27, 2003

RECEIVED
SEP 09 2003
TECH CENTER 1600/2000

49.	Durrant, Anticancer Drugs (1997) 8:727-733 ✓
50.	Epstein, Hum. Pathol. (1995) 26(2):223-229 ✓
51.	Evans et al., Am. J. Obstet. Gynecol. (1994) 171(4):1055-1057 ✓
52.	Falk et al., Nature (1991) 351:290-296 ✓
53.	Fong et al., J. Immunol. (1997) 159:3113-3117 ✓
54.	Foon et al., J. Clin. Invest. (1995) 96:334-342 ✓
55.	Fortier et al., J. Nat. Cancer Inst. (1999) 91(19):1635-1640 ✓
56.	Funakoshi et al., J. Immunother. Emphasis Tumor Immunol. (1996) 19:93-101 ✓
57.	Gaiddon et al., Endocrinology (1995) 136(10):4331-4338 ✓
58.	Gao et al., Prostate (1997) 31:264-281 ✓
59.	Ghossein et al., J. Clin. Oncol. (1995) 13:1195-2000 ✓
60.	Goffman et al., Cancer Genet. Cytogenet. (1983) 8(3):197-202 ✓
61.	Grever et al., J. Comp. Neurol. (1996) 376(2):306-314 ✓
62.	Hall et al., Nucleic Acids Research (1996) 24(6):1119-1126 ✓
63.	Hamilton et al., Biochem. Biophys. Res. Commun. (1999) 261:646-651 ✓
64.	Hebbes et al., Mol. Immunol. (1989) 26(9):865-873 ✓
65.	Henderson et al., Cancer Res. (1996) 56:3763-3770 ✓
66.	Herlyn et al., Cancer Immunol. Immunother. (1996) 43:65-76 ✓
67.	Heston et al., Clin. Chem. (1995) 41:1687-1688 ✓
68.	Hodge et al., Int. J. Cancer (1995) 63:231-237 ✓
69.	Honore et al., J. Biol. Chem. (1995) 270:28780 ✓
70.	Hunt et al., Science (1992) 255:1261-1263 ✓
71.	Isaacs et al., Cancer Surv. (1995) 23:19-32 ✓
72.	Israeli et al., Cancer Res. (1994) 54:1807 ✓
73.	Iyer et al., J. Am. Chem. Soc. (1990) 112:1253-1254 ✓
74.	Iyer et al., J. Org. Chem. (1990) 55:4693-4698 ✓
75.	J. Urol. (1995) 154(2 Pt 1):474-478 ✓
76.	Jakobovits, Exp. Opin. Invest. Drugs (1998) 7(4):607-614 ✓
77.	Jarrard, J. Urol. (2000) 163(4):1189-1190 ✓
78.	Jones et al., Nature (1986) 321:522-525 ✓
79.	Kasprzyk et al., Cancer Res. (1992) 52:2771-2776 ✓

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Docket Number 511582002100	Application Number 09/697,206
		Applicant	Daniel E.H. AFAR et al.
		Filing Date October 26, 2000	Group Art Unit 1642
		Mailing Date August 27, 2003	

80.	Kennedy et al., Nat. Genet. (1996) 12(3):329-331
81.	Klein et al., Nature Medicine (1997) 3:402-408
82.	Kozak, Mol. Cell Biol. (1989) 9:5073-5080
83.	Lethe et al., Int. J. Cancer (1998) 76(6):903-908
84.	Li et al., Cell (1992) 69:915
85.	Li et al., J. Biol. Chem. (2000) 275(30):23053-23058
86.	Marrogi et al., J. Cutan. Pathol. (1999) 26(8):369-378
87.	Merrill et al., J. Urol. (2000) 163(2):503-512
88.	Minimoto et al., Cancer Detect. Prev. (2000) 24(1):1-12
89.	Morton and Myszka, Methods in Enzymology (1998) 295:268
90.	Moun et al., Cancer Res. (1994) 54:6160-6166
91.	Muller et al., MCB (1991) 11:1785
92.	Murphy et al., Prostate (1996) 29:371-380
93.	O'Brian, Oncol. Rep. (1998) 5(2):305-309
94.	Ozaki et al., Blood (1997) 90:3179-3186
95.	Parker et al., J. Immunol. (1992) 149:3580-3587
96.	Parker et al., J. Immunol. (1994) 152:163-175
97.	Partridge et al., Antisense and Nucleic Acid Drug Development (1996) 6:169-175
98.	Peshwa et al., Prostate (1998) 36:129-138
99.	Peterziel et al., Oncogene (1999) 18(46):6322-6329
100.	Polascik et al., J. Urol. (1999) 162(2):293-306
101.	Raju et al., Exp. Cell Res. (1997) 235(1):145-154
102.	Reiter et al., Proc. Natl. Acad. Sci. USA (1998) 95:1735
103.	Restifo, Curr. Opin. Immunol. (1996) 8:658-663
104.	Reynolds et al., Int. J. Cancer (1997) 72:972-976
105.	Ribas et al., Cancer Res. (1997) 57:2865-2869
106.	Richardson et al., Proc. Natl. Acad. Sci. USA (1995) 92:3137-3141
107.	Riechmann et al., Nature (1988) 332:323-327
108.	Robertson et al., Methods Mol. Biol. (1998) 98:121-154
109.	Sawai et al., Fetal Diagn. Ther. (1996) 11(6):407-413
110.	Schlessenger et al., Curr. Opin. Genet. Dev. (1994) 4:25

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SEP 05 2003



Form PTO-1449		Docket Number 511582002100	Application Number 09/697,206
INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Applicant Daniel E.H. AFAR et al.	
		Filing Date October 26, 2000	Group Art Unit 1642
		Mailing Date August 27, 2003	

111.	Schwartz et al., J. Immunol. (1985) 135(4):2598-2608
112.	Sharief et al., Biochem. Mol. Biol. Int. (1994) 33(3):567-574
113.	Shepard et al., J. Clin. Immunol. (1991) 11:117-127
114.	Shnyreva et al., J. Biol. Chem. (2000) 19:275:15498-15503
115.	Sims et al., J. Immunol. (1993) 151:2296
116.	Sodee et al., Clin. Nuc. Med. (1996) 21:759-766
117.	Stephan et al., Urology (2000) 55(4):560-563
118.	Storrie et al., Methods Enzymology (1990) 182:203-225
119.	Su et al., Proc. Natl. Acad. Sci. USA (1996) 93:7252
120.	Takahama, Forensic Sci. Int. (1996) 80(1-2):63-69
121.	Thomas, Proc. Natl. Acad. Sci. USA (1980) 77:5201-5205
122.	Thomas and Capecchi, Cell (1987) 51:503
123.	Thorson et al., Mod. Pathol. (1998) 11(6):543-551
124.	Tjoa et al., Prostate (1996) 28:65-69
125.	Tsunenari et al., Blood (1997) 90:2437-2444
126.	Tulchinsky et al., Int. J. Mol. Med. (1999) 4(1):99-102
127.	Van den Eynde and Boon, Int. J. Clin. Lab. Res. (1997) 27:81-86
128.	Vaughan et al., Nature Biotechnology (1998) 16:535-539
129.	Velders et al., Cancer Res. (1995) 55:4398-4403
130.	Verhoeven et al., Science (1988) 239:1534-1536
131.	Verkaik et al., Urol. Res. (1995) 25:373-384
132.	Wagner et al., Hybridoma (1997) 16:33-40
133.	Walter et al., Nat. Genetics (1994) 7:22
134.	Welch et al., Int. J. Cancer (1989) 43:449-457
135.	Welford, Opt. Quant. Elect. (1991) 23:1
136.	Wells et al., Gene (1985) 34:315
137.	Wells et al., Philos. Trans. R. Soc. London Ser. A (1986) 317:415
138.	Wolff et al., Cancer Res. (1993) 53:2560-2565
139.	Xiao et al., Blood (2000) 96(2):699-704
140.	Xue et al., Prostate (1997) 30:73-78
141.	Yeatment et al., Clin. Exp. Metastasis (1996) 14(3):246-252

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.



<p>Form PTO-1449</p> <p>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</p> <p><i>(Use several sheets if necessary)</i></p>		
	Docket Number 511582002100	Application Number 09/697,206
	Applicant	Daniel E.H. AFAR et al.
	Filing Date October 26, 2000	Group Art Unit 1642
Mailing Date August 27, 2003		

142. Zhong et al., Leuk. Res. (1996) 20:581-589
 143. Zoller et al., Nucl. Acids Res. (1987) 10:6487

RECEIVED
SEP 09 2003
TECH CENTER 1600/2900

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.